Aquestive Therapeutics, Inc. (AQST) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 10-K filed 2026-03-04

How it makes money

It earns revenue by manufacturing specialized film-based drugs for licensees and by providing development services, with profit sensitivity tied to partner-driven volume and successful product commercialization.

Aquestive acts as a specialized contract manufacturer and technology developer. It earns income when licensees place purchase orders for products it manufactures, or when partners pay development fees and royalties based on their commercial success. Because it generally does not control marketing or pricing, its financial results are heavily dependent on its partners' ability to successfully sell the products in their respective markets.

What protects it: the moat

It relies on proprietary film technology, manufacturing techniques, and intellectual property to deter competitors from duplicating its drug delivery platform.

The company positions its PharmFilm technology as a unique way to deliver medication, claiming it offers clinical advantages over traditional dosage forms. Management asserts that its proprietary formulations and production methods act as a barrier to entry, though it faces ongoing competition from others developing alternate delivery methods for central nervous system and allergy treatments.

What growth costs

Growth requires substantial capital investment in drug development, clinical trials, and regulatory processes, alongside potential funding for future operations and debt obligations.

To grow, the company must fund expensive research and development for new candidates like Anaphylm. It also faces significant financial requirements to support its ongoing operations and meet future debt repayment schedules, necessitating constant access to capital markets.

What could damage it

Failure to secure FDA regulatory approval for key candidates like Anaphylm would permanently impair the company's ability to monetize its core pipeline investment.

Since the business model depends on successfully bringing its internal technology and candidates through the regulatory process to market, a rejection or significant deficiency finding by the FDA creates a causal chain that prevents the company from reaching the commercialization stage, thereby invalidating its R&D expenditures and planned revenue streams.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Other companies in Drug Manufacturers - Specialty & Generic